Showing results (311-320 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|June 27, 2024
The origin of ferritin reference intervals: a systematic reviewJudy Truong, Kanza Naveed, Daniel Beriault, et al.
The Lancet. Haematology|June 17, 2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 studyYu Hu, Xiaofan Liu, Hu Zhou, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
The Lancet. Haematology|June 6, 2024
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trialJillian R Gunther, Jie Xu, Manoop S Bhutani, et al.
The Lancet. Haematology|May 11, 2024
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementKai Rejeski, Michael D Jain, Nirali N Shah, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
The Lancet. Haematology|April 11, 2024
Methodological challenges in the development of endpoints for myelofibrosis clinical trialsGiovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet. Haematology|February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialRudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
The Lancet. Haematology|February 2, 2026
Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?Fernando Barroso Duarte, Carmelo Gurnari, Donal P McLornan
The Lancet. Haematology|December 11, 2025
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialArnon P Kater, Ann Janssens, Herbert Eradat, et al.
Pageof 73